Olcican 450 450 mg FC Tablet
PDF Leaflet Revision Date: 15 July 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment and prevention of CMV disease in at-risk patients.
Dosage (summary)
900 mg twice daily for 21 days for induction; 900 mg once daily for maintenance.
Special Populations
- Renal impairment
- Elderly
- Paediatric patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; potential teratogenic effects.
Key Drug Interactions
- Imipenem-cilastatin
- Zidovudine
- Didanosine
- Probenecid
Contraindications
- Hypersensitivity to valganciclovir or ganciclovir
- Breastfeeding
Common side effects
- Neutropenia
- Anaemia
- Thrombocytopenia
- Gastrointestinal disturbances
Counselling Points
- Take with food
- Use effective contraception during treatment
- Monitor for signs of infection or bleeding
Serious warnings
- Myelosuppression
- Potential teratogenicity
- Risk of severe adverse reactions with overdose
Important Disclaimer
The Olcican 450 450 mg FC Tablet professional information leaflet below is the property of Trinity Pharma and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
